Journal Mobile Options
Table of Contents
Vol. 69, No. 1, 2003
Issue release date: September 2003

Effects of Camonagrel, a Selective Inhibitor of Platelet Thromboxane Synthase, on the Platelet-Subendothelium Interaction

Villalobos M.A. · De La Cruz J.P. · Escalante R. · Arrebola M.M. · Guerrero A. · Sánchez de la Cuesta F.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The aim of this study was to compare the effects of a new thromboxane synthase inhibitor, camonagrel, on platelet aggregation and platelet-subendothelium interaction under flow conditions, in comparison with a standard thromboxane synthase inhibitor (dazoxiben) and a cyclooxygenase inhibitor (acetylsalicylic acid). With respect to platelet aggregation in whole blood, the 50% inhibitory concentrations (IC50) of camonagrel were between 318 and 797 µmol/l after induction with collagen and adenosine 5′-diphosphate, respectively. For inhibition of thromboxane B2 synthesis, the IC50 values were 868 ± 68 µmol/l; prostaglandin E2 was inhibited only by acetylsalicylic acid (IC50 for camonagrel >2,000 µmol/l), and the leukocyte 6-keto-PGF level was increased by camonagrel. The greatest reduction in percentage subendothelial surface occupied by platelets (mainly in the thrombi) after blood perfusion was seen after incubation with camonagrel in the range of concentrations that inhibited collagen-induced platelet aggregation. In conclusion, camonagrel reduced platelet-subendothelium interaction under flow conditions, showing this effect in a range of concentrations lower than in inhibition of platelet aggregation.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B: Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 1976;261:558–560.
  2. Bunting S, Gryglewski R, Moncada S, Vane JR: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976;12:897–913.
  3. Maguire DE, Wallis RB: In vivo redirection of prostaglandin endoperoxides into 6-keto-PGF formation by thromboxane synthase inhibitors in the rats. Thromb Res 1983;32:15–27.
  4. Mayeux PR, Kadowitz PJ, McNamara DB: Evidence for a bi-directional prostaglandin endoperoxide shunt between platelets and the bovine coronary artery. Biochim Biophys Acta 1989;1011:18–24.
  5. Jones EW, Cockbill SR, Cowley AJ, Hanley SP, Heptinstall S: Effects of dazoxiben and low-dose aspirin on platelet behaviour in man. Br J Clin Pharmacol 1983;15:39–44.
  6. Tayler HM, Saxton CA, Parry MJ: Administration to man of UK 37.248-01, a selective inhibitor of thromboxane synthase. Lancet 1981;i:629–632.
  7. Mayeux PR, Morton HE, Gillard J, Lord A, Morinelli TA, Boehm A, Mais DE, Halushka PV: The affinities of prostaglandin H2 and thromboxane A2 for their receptors are similar in washed human platelets. Biochem Biophys Res Commun 1988;157:733–739.
  8. Gryglewski RJ, Szczeklik A, Korbut R, Swies J, Musial J, Krzanowski M, Maga P: The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel – a new thromboxane synthase inhibitor. Wien Klin Wochenschr 1995;107:283–289.
  9. Korbut R, Grygleski RJ: A paradox of thrombogenesis by streptokinase and its prevention by iloprost and camonagrel. Methods Find Exp Clin Pharmacol 1996;18:167–174.
  10. Korbut R, Gryglewski RJ: The effect of prostacyclin and nitric oxide on deformability of red blood cells in septic shock in rats. J Physiol Pharmacol 1996;47:591–599.
  11. De La Cruz JP, Moreno A, Ruiz-Ruiz MI, García Campos JM, Sanchez de la Cuesta F: Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal vascularization in experimental diabetes. Eur J Pharmacol 1998;29:81–85.
  12. Cardinal DC, Flower RJ: The electronic aggregometer: A novel device for assessing platelet behaviour in blood. J Pharmacol Methods 1980;3:135–158.
  13. Baumgartner HR, Haudenschild C: Adhesion to subendothelium. Ann NY Acad Sci 1972;201:22–36.
  14. Baumgartner HR: Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood. Haemostasis 1979;8:340–352.
  15. Baumgartner HR, Muggli R: Adhesion and aggregation: Morphological demonstration and quantitation in vivo and in vitro; in Gordon JL (ed): Platelets in Biology and Pathology. Amsterdam, Biomedical Press, 1976, pp 23–60.
  16. De La Cruz JP, Bellido I, Camara S, Martos F, Sánchez de la Cuesta F: Effects of acetylsalicylic acid on platelet aggregation in male and female whole blood: An in vitro study. Scand J Haematol 1986;36:394–297.
  17. De La Cruz JP, Camara S, Bellido I, Carrasco T, Sánchez de la Cuesta F: Platelet aggregation in human whole blood after chronic administration of aspirin. Thromb Res 1987;46:133–140.
  18. López-Farre A, Caramelo C, Esteban A, Alberola ML, Millas I, Monton M, Casado S: Effect of aspirin on platelet-neutrophil interaction: Role of nitric oxide and endothelin-1. Circulation 1995;91:2080–2088.
  19. De La Cruz JP, Blanco E, Sánchez de la Cuesta F: Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway. Eur J Pharmacol 2000;397:35–41.
  20. De La Cruz JP, Guerrero A, Paniego MJ, Arranz I, Moreno A, Sánchez de la Cuesta F: Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy. Naunyn Schmiedebergs Arch Pharmacol 2002;365:96–101.
  21. Perez-Requejo JL, Aznar J, Santos MT, Valles J: Early platelet-collagen interactions in whole blood and their modifications by aspirin and dipyridamole evaluated by a new method (BASIC wave). Thromb Haemost 1985;54:799–803.
  22. De La Cruz JP, Villalobos MA, García PJ, Smith-Agreda JM, Sanchez de la Cuesta F: Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers. Eur J Clin Pharmacol 1995;46:497–502.
  23. Escolar G, Albors M, Garrido M, Bioque G, Díaz-Ricart M, Carretero M, Ordinas A: Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: Potentiation of antiplatelet effects of aspirin. Eur J Clin Invest 1998;28:562–568.
  24. Terres W, Hamm CW, Ruchelka A, Weilip A, Kupper W: Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty. J Cardiovasc Pharmacol 1992;19:190–193.
  25. Wolkow PP, Bartus JB, Gryglewski RJ: Pneumotoxicity of lipopolysaccharide in nitric oxide-deficient rats is limited by a thromboxane synthase inhibitor. J Physiol Pharmacol 1997;48:645–653.
  26. Olszanecki R, Chlopicki S: Endotoxinaemia in rats: Role of NO, PAF and TxA2 in pulmonary neutrophil sequestration and hyperlactataemia. J Physiol Pharmacol 1999;501:443–454.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50